ホーム › 卵巣がん › サウスダコタ › Sioux Falls
Sioux Falls、SDにおける卵巣がんの臨床試験
Sioux Fallsとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第3相
- Sanford Health, Sioux Falls
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Avera Medical Group, Sioux Falls
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Sanford Cancer Center /ID# 274901, Sioux Falls
- Avera Cancer Institute - Sioux Falls /ID# 276226, Sioux Falls
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Site 0132 - Avera Cancer Institute, Sioux Falls
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- Avera Cancer Institute - Sioux Falls /ID# 278627, Sioux Falls
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- Sanford Cancer Center-Sioux Falls, Sioux Falls
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第2相
- Avera Cancer Institute Sioux Falls, Sioux Falls
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
被験者募集中第3相
- Site 0112, Sioux Falls
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Avera Cancer Institute, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
被験者募集中第2/3相
- Sanford Cancer Center Gynecologic Oncology, Sioux Falls
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
被験者募集中第3相
- Avera Medical Group Gynecologic, Sioux Falls
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Avera Cancer Institute, Sioux Falls
Avera Cancer Sequencing and Analytics Protocol (ASAP)
被験者募集中観察研究
- Avera Cancer Institute, Sioux Falls
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Sioux Fallsにおける他の研究
- 非小細胞肺癌19件の研究
- 乳がん18件の研究
- 肺がん14件の研究
- がん（全種類）13件の研究
- 子宮内膜がん11件の研究
- 転移性癌10件の研究
- 大腸癌9件の研究
- 頭頸部扁平上皮癌9件の研究
- 心不全7件の研究
- 結腸癌7件の研究
- トリプルネガティブ乳がん7件の研究
- 前立腺がん7件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。